Geron Corp GERN:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD

After Hours: Last | 05/03/24 EDT

3.94

+0.01 (+0.25%)

Volume

68,554

3.93

-0.02 (-0.51%)

Volume

8,352,972

52 week range

1.64 - 4.30

Open4.00
Day High4.02
Day Low3.74
Prev Close3.95
52 Week High4.30
52 Week High Date04/29/24
52 Week Low1.64
52 Week Low Date03/13/24

Key Stats

Market Cap2.307B
Shares Out586.91M
10 Day Average Volume11.76M
Dividend-
Dividend Yield-
Beta0.46
YTD % Change86.26

KEY STATS

Open4.00
Day High4.02
Day Low3.74
Prev Close3.95
52 Week High4.30
52 Week High Date04/29/24
52 Week Low1.64
52 Week Low Date03/13/24
Market Cap2.307B
Shares Out586.91M
10 Day Average Volume11.76M
Dividend-
Dividend Yield-
Beta0.46
YTD % Change86.26

RATIOS/PROFITABILITY

EPS (TTM)-0.34
P/E (TTM)-11.40
Fwd P/E (NTM)-11.07
EBITDA (TTM)-193.502M
ROE (TTM)-112.29%
Revenue (TTM)237,000.003
Gross Margin (TTM)-
Net Margin (TTM)-77,690.72%
Debt To Equity (MRQ)33.05%

EVENTS

Earnings Date08/01/2024(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest On Geron Corp

Cramer's Lightening Round: BTU, TTD, GERNApril 10, 2024CNBC.com
Cramer's Lightning Round: Trade Desk is 'great'April 10, 2024CNBC.com

Content From Our Affiliates

Buy Rating Affirmed: Anticipating Imetelstat’s Approval and Market PotentialMay 2, 2024TipRanks
Biotech Alert: Searches spiking for these stocks todayMay 2, 2024TipRanks
Geron reports Q1 EPS (9c), consensus (10c)May 2, 2024TipRanks
Analysts Conflicted on These Healthcare Names: Dyne Therapeutics (DYN) and Geron (GERN)April 30, 2024TipRanks
Geron downgraded to Neutral from Outperform at BairdApril 30, 2024TipRanks

Profile

Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical...

John Scarlett M.D.

Chairman of the Board, President, Chief Executive Officer

Andrew Grethlein Ph.D.

Executive Vice President, Chief Operating Officer

Michelle Robertson

Chief Financial Officer, Executive Vice President - Finance, Treasurer

Scott Samuels Esq.

Executive Vice President, Chief Legal Officer, Secretary

Melissa Behrs

Executive Vice President - Business Operations, Chief Alliance Officer

Address

919 East Hillsdale Boulevard, Suite 250

Foster City, CA

94404

United States

https://www.geron.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
KURA Kura Oncology Inc	20.63	+0.04	+0.19%
DYN Dyne Therapeutics Inc	26.08	+0.08	+0.31%
KROS Keros Therapeutics Inc	60.57	+3.47	+6.08%
RNA Avidity Biosciences Inc	26.45	+0.87	+3.40%
CLDX Celldex Therapeutics Inc	42.56	+1.70	+4.16%